Cargando…
SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis
Background: Agranulocytosis is the most feared side effect of antithyroid-drug therapy. In the largest series, agranulocytosis occurred in 0.35 percent receiving methimazole. The causative antithyroid-drug should be stopped and treatment includes broad-spectrum antibiotics and granulocyte-colony sti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552568/ http://dx.doi.org/10.1210/js.2019-SAT-600 |
_version_ | 1783424622698430464 |
---|---|
author | Choi, Dughyun Kim, Bo-Yeon Jung, Chan-Hee Kim, Chul-Hee Kang, Sung-Koo Mok, Ji-Oh |
author_facet | Choi, Dughyun Kim, Bo-Yeon Jung, Chan-Hee Kim, Chul-Hee Kang, Sung-Koo Mok, Ji-Oh |
author_sort | Choi, Dughyun |
collection | PubMed |
description | Background: Agranulocytosis is the most feared side effect of antithyroid-drug therapy. In the largest series, agranulocytosis occurred in 0.35 percent receiving methimazole. The causative antithyroid-drug should be stopped and treatment includes broad-spectrum antibiotics and granulocyte-colony stimulation factor may be needed in selected patients(1). Here, we report a case of agranulocytosis relapse after the recovery of methimazole-induced agranulocytosis. Case: A 35-year-old woman was admitted to hospital by fever lasted 3 days. The patient was diagnosed hyperthyroidism 3 weeks ago, and she was taking methimazole 15mg daily. Lab finding of admission day was 370/mm(3) of granulocyte count, normal C-reactive protein, 4.64ng/mL of T3, 7.66ng/dL of free T4, below 0.05uIU/dL of Thyroid-stimulating hormone. After isolated admission care including methimazole stop and follow-up of 3 days, granulocyte count was elevated to 1,190/mm(3). The patient was discharged without restarting other antithyroid-drugs. 4 days later, the patient admitted again by fever and sore throat. The granulocyte count was 10/mm(3) with normal range of C-reactive protein, above 6.51ng/mL of T3, above 7.77ng/dL of free T4, below 0.05uIU/dL of Thyroid-stimulating hormone. We used granulocyte-colony stimulation factor and intravenous cefepime. After 4 days, granulocyte count improved to 1,610/mm(3) and fever was subsided. After recovery, total thyroidectomy was performed for hyperthyroidism. The patient is now taking levothyroxine in the outpatient clinic without further additional agranulocytosis episodes. Conclusion: We are reporting a relapse of agranulocytosis after recovery of methimazole-induced agranulocytosis. Even if the antithyroid-drug is not used again after the recovery of agranulocytosis, attention to relapse of agranulocytosis and education of the patient may be necessary. Reference: 1. David S. Cooper, M.D. (March 3, 2005). “Antithyroid drugs" New England Journal of Medicine 2005; 352:905-917 |
format | Online Article Text |
id | pubmed-6552568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65525682019-06-13 SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis Choi, Dughyun Kim, Bo-Yeon Jung, Chan-Hee Kim, Chul-Hee Kang, Sung-Koo Mok, Ji-Oh J Endocr Soc Thyroid Background: Agranulocytosis is the most feared side effect of antithyroid-drug therapy. In the largest series, agranulocytosis occurred in 0.35 percent receiving methimazole. The causative antithyroid-drug should be stopped and treatment includes broad-spectrum antibiotics and granulocyte-colony stimulation factor may be needed in selected patients(1). Here, we report a case of agranulocytosis relapse after the recovery of methimazole-induced agranulocytosis. Case: A 35-year-old woman was admitted to hospital by fever lasted 3 days. The patient was diagnosed hyperthyroidism 3 weeks ago, and she was taking methimazole 15mg daily. Lab finding of admission day was 370/mm(3) of granulocyte count, normal C-reactive protein, 4.64ng/mL of T3, 7.66ng/dL of free T4, below 0.05uIU/dL of Thyroid-stimulating hormone. After isolated admission care including methimazole stop and follow-up of 3 days, granulocyte count was elevated to 1,190/mm(3). The patient was discharged without restarting other antithyroid-drugs. 4 days later, the patient admitted again by fever and sore throat. The granulocyte count was 10/mm(3) with normal range of C-reactive protein, above 6.51ng/mL of T3, above 7.77ng/dL of free T4, below 0.05uIU/dL of Thyroid-stimulating hormone. We used granulocyte-colony stimulation factor and intravenous cefepime. After 4 days, granulocyte count improved to 1,610/mm(3) and fever was subsided. After recovery, total thyroidectomy was performed for hyperthyroidism. The patient is now taking levothyroxine in the outpatient clinic without further additional agranulocytosis episodes. Conclusion: We are reporting a relapse of agranulocytosis after recovery of methimazole-induced agranulocytosis. Even if the antithyroid-drug is not used again after the recovery of agranulocytosis, attention to relapse of agranulocytosis and education of the patient may be necessary. Reference: 1. David S. Cooper, M.D. (March 3, 2005). “Antithyroid drugs" New England Journal of Medicine 2005; 352:905-917 Endocrine Society 2019-04-30 /pmc/articles/PMC6552568/ http://dx.doi.org/10.1210/js.2019-SAT-600 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Thyroid Choi, Dughyun Kim, Bo-Yeon Jung, Chan-Hee Kim, Chul-Hee Kang, Sung-Koo Mok, Ji-Oh SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis |
title | SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis |
title_full | SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis |
title_fullStr | SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis |
title_full_unstemmed | SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis |
title_short | SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis |
title_sort | sat-600 relapse of agranulocytosis after recovery of methimazole-induced agranulocytosis |
topic | Thyroid |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552568/ http://dx.doi.org/10.1210/js.2019-SAT-600 |
work_keys_str_mv | AT choidughyun sat600relapseofagranulocytosisafterrecoveryofmethimazoleinducedagranulocytosis AT kimboyeon sat600relapseofagranulocytosisafterrecoveryofmethimazoleinducedagranulocytosis AT jungchanhee sat600relapseofagranulocytosisafterrecoveryofmethimazoleinducedagranulocytosis AT kimchulhee sat600relapseofagranulocytosisafterrecoveryofmethimazoleinducedagranulocytosis AT kangsungkoo sat600relapseofagranulocytosisafterrecoveryofmethimazoleinducedagranulocytosis AT mokjioh sat600relapseofagranulocytosisafterrecoveryofmethimazoleinducedagranulocytosis |